Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Barber KE, Martineau M, Harewood L, Stewart M, Cameron E, Strefford JC et al. Amplification of the ABL gene in T-cell acute lymphoblastic leukemia. Leukemia 2004; 18: 1153–1156.

    Article  CAS  PubMed  Google Scholar 

  2. Graux C, Cools J, Melotte C, Quentmeier H, Ferrando A, Levine R et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004; 36: 1084–1089.

    Article  CAS  PubMed  Google Scholar 

  3. Burmeister T, Gökbuget N, Reinhardt R, Rieder H, Hoelzer D, Schwartz S . NUP214-ABL1 in adult T-ALL: the GMALL study group experience. Blood 2006; 108: 3556–3559.

    Article  CAS  PubMed  Google Scholar 

  4. Stergianou K, Fox C, Russell NH . Fusion of NUP214 to ABL1 on amplified episomes in T-ALL—implications for treatment. Leukemia 2005; 19: 1680–1681.

    Article  CAS  PubMed  Google Scholar 

  5. De Keersmaecker K, Versele M, Cools J, Superti-Furga G, Hantschel O . Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases. Leukemia 2008, e-pub ahead of print.

  6. De Keersmaecker K, Porcu M, Gielen O, Cools J . LCK is a critical signaling effector in NUP214-ABL1 positive T-ALL. Haematologica 2008; 93 (s1) (abstract (0476)).

  7. Quintas-Cardama A, Tong W, Manshouri T, Vega F, Lennon PA, Cools J et al. Activity of tyrosine kinase inhibitors against NUP214-ABL1-positive T cell malignancies. Leukemia 2008; 22: 1117–1124.

    Article  CAS  PubMed  Google Scholar 

  8. Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111: 1827–1833.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deenik, W., Beverloo, H., van der Poel-van de Luytgaarde, S. et al. Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia. Leukemia 23, 627–629 (2009). https://doi.org/10.1038/leu.2008.318

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.318

This article is cited by

Search

Quick links